Abbott
Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
Published in Telemedicine Law Weekly, October 10th, 2009
Abbott (NYSE:ABT) announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial. PROSPECT is the first prospective natural history study to evaluate the role of vulnerable plaque in unexpected heart attacks and the natural progression of coronary artery disease. Results were presented today during the late-breaking clinical trials session by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center, during the 2009 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting.
"We know that certain vulnerable plaques lead to sudden cardiac death, but...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Law Weekly
More Articles from Telemedicine Law Weekly
- 3DIcon Corporation
3DIcon Retains Trontz Public Relations as Agency of Record - Acid Reflux Disease
Investigators at Tohoku University publish new data on acid reflux disease - ACR Image Metrix
ACR Image Metrix Completes Successful Second Year as Imaging CRO - Adenomatous Polyp
New adenomatous polyp data have been reported by researchers at University of Amsterdam - Advantest Corporation
Advantest Targets New Markets with Terahertz Wave Measurement Technology - American Roentgen Ray Society
Radiologists find a technique to significantly reduce patient radiation dose during CT angiography - More from this issue of Telemedicine Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
